ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Finally we can compare products

<< Previous

Bullboard Posts

Next >>

Comment by BottomBrokeron Dec 20, 2022 9:35am

218 Views

Post# 35181803

RE:RE:RE:Finally we can compare products

I get the point, too.

So when DOES PMN announce they are in the race? Many expected milestones have come and gone. IND filing was expected in Dec. Now we're looking at what? Q2 of 2023? Maybe Q3? Maybe..........? And then what about trials? Are we looking at 2024 before they even (might!) begin.

PMN can't compare results they don't have.

<< Previous

Bullboard Posts

Next >>

From now on, dynaCERT instead of Bitcoin or NVIDIA?